Regeneron shares rise despite missing earnings estimates

5 May 2017

Shares of Regeneron Pharmaceuticals (Nasdaq: REGN) closed up 6.7% to $434.31 on Thursday, after it reported first-quarter 2017 financials with earnings missing analysts’ expectations but sales better than they had expected

Total revenues for the quarter reached $1.32 billion, just beating Wall Street consensus forecasts of $1.3 billion. On a generally accepted accounting principles (GAAP) basis, net income was $249 million, up 38%. Non-GAAP income came in at $337 million, or $2.91 per share - diluted, rises of 23% and 22% respectively, but missing forecasts for $3.07.

Net product sales were up 9.4% at $858 million in the first quarter of 2017, compared to $784 million in the first quarter of 2016. Eylea (aflibercept) net product sales in the USA, where Regeneron sales the ophthalmic drug, were $854 million in the first quarter of 2017, compared to $781 million in the first quarter of 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK